Cardiovascular mortality in patients with prostate cancer exposed to androgen deprivation therapy

Actas urologicas españolas
J I Monzó-Gardiner, F Herranz-Amo

Abstract

A relationship between the administration of GnRH agonists and the risk of acute myocardial infarction (AMC) in patients with prostate cancer has been showed in the third observational study published in April 2014. The association AMC-orchiectomy was not found in any of these studies. Define risk factors for cardiovascular disease in patients treated with GnRH agonist. Their probable underlying pathogenic mechanism in the myocardium and peripheral vascular tree was also analyzed. English articles cited in PubMed were reviewed. No time period is specified. The last search date was 11/30/14. In patients with coronary history of AMC or congestive heart failure, hormonal neoadjuvant therapy increased cardiovascular mortality rates (HR: 1.96, IC 95%: 1.04-3.71; P=.04) as well as cardiovascular-specific mortality rates (AHR: 3.28; IC 95%: 1.01-10.64; P=.048). Two possible mechanisms can be involved: a) direct mechanism through myocardial receptor for GnRH/PKA along with atherogenic plaques; and b) indirect mechanism related with metabolic disturbances. Patients with AMC or congestive heart failure history could present a higher risk of death related to the use of GnRH agonists. In these cases, should carefully consider appropriatene...Continue Reading

References

May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Dec 4, 2004·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·F TanriverdiP M G Bouloux
Sep 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy L KeatingMatthew R Smith
Jun 15, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony V D'AmicoPhilip W Kantoff
Jan 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mack RoachMiljenko V Pilepich
Nov 26, 2008·Progress in Cardiovascular Diseases·Bente HalvorsenPål Aukrust
Mar 17, 2009·The Journal of Urology·Philip J Saylor, Matthew R Smith
Feb 4, 2010·CA: a Cancer Journal for Clinicians·Glenn N LevineUNKNOWN American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer So
Feb 22, 2011·Journal of Neuroendocrinology·F DongJ Ren
Dec 8, 2011·JAMA : the Journal of the American Medical Association·Paul L NguyenToni K Choueiri

❮ Previous
Next ❯

Citations

Jan 25, 2017·Nature Reviews. Urology·Antonello VecciaOrazio Caffo
Jun 6, 2020·Heart Failure Reviews·Vittore CeredaGaetano Lanzetta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.